Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities

Abstract

Psoriasis is a chronic, inflammatory, multisystem disease that affects up to 3.2% of the US population. This guideline addresses important clinical questions that arise in psoriasis management and care, providing recommendations on the basis of available evidence.

Underscreening of depression in U.S. outpatients with atopic dermatitis and psoriasis

“…D ear E ditor , Psoriasis and atopic dermatitis are associated with depression, anxiety and suicidality . As such, mental health screening by dermatologists is recommended in these disorders . However, rates and predictors of mental health screening among people with these skin diseases have not been elucidated.…”

<p>A narrative review of psoriasis and multiple sclerosis: links and risks</p>

“…Psoriasis (PsO) has been associated with an increased risk of multiple comorbidities including psoriatic arthritis (PsA), cardiovascular disease, diabetes mellitus, metabolic syndrome, inflammatory bowel disease, and certain malignancies. 1,2 Multiple sclerosis (MS) has also been reported as a comorbidity in individuals with PsO, and vice versa. 3,4 This link between the two diseases may be somewhat unsurprising as both PsO and MS are inflammatory disorders and exhibit similarities in genetic risk variants and inflammatory pathways.…”

Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis

“…1,2 Psoriasis has a negative influence on patients' quality of life and increases the risk for early mortality and prevalence of comorbidities, including cardiovascular disease, hypertension, hyperlipidemia, diabetes, and depression. [3][4][5] Complete or nearly complete clearance is now achievable with available biologic treatments targeting various cytokines involved in disease pathogenesis, namely interleukin 17 , IL-23, and tumor necrosis factor α 6,7 ; however, durability of response with many biologic agents is limited in clinical practice after 1 to 2 years due to loss of treatment effect over time. [8][9][10] A key regulatory cytokine, IL-23 is essential for pathogenic T helper 17 cell differentiation, activation, and survival.…”